Research programme: immunomodulators - PDS Biotechnology Corporation

Drug Profile

Research programme: immunomodulators - PDS Biotechnology Corporation

Alternative Names: PDS0102A; PDS0102B; PDS0103; PDS0204

Latest Information Update: 28 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PDS Biotechnology Corporation
  • Developer National Cancer Institute (USA); PDS Biotechnology Corporation
  • Class Cancer vaccines; Influenza virus vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Breast cancer; Prostate cancer
  • No development reported Influenza virus infections; Malignant melanoma

Most Recent Events

  • 28 Mar 2018 No recent reports of development identified for preclinical development in Influenza-virus-infections in USA (SC, Injection)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Malignant-melanoma in USA (SC, Injection)
  • 09 Feb 2016 PDS Biotechnology establishes CRADA with National Institutes of Health for the development of Versamune® platform in Breast and Prostate cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top